Current treatment and clinical trial developments for ductal carcinoma in situ of the breast

Oncologist

Volumn 12, Issue 11, 2007, Pages 1276-1287

  Boughey, Judy C ^a   Gonzalez, Ricardo J ^b   Bonner, Everett ^c   Kuerer, Henry M ^b,d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d Box 444 ^*  (United States)

Author keywords

Ductal carcinoma in situ; Radiation; Tamoxifen; Trastuzumab

Indexed keywords

CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST BIOPSY; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARCINOMA IN SITU; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOADING DRUG DOSE; MAMMOGRAPHY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SEGMENTAL MASTECTOMY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MEDICAL ONCOLOGY; RESEARCH DESIGN; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 36849024827     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-11-1276     Document Type: Review

References (69)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: A dilemma. J Natl Cancer Inst Monogr 1997:151-156.
3. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: Risk factors and screening patterns. J Natl Cancer Inst 2001;93:1811-1817.
4. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: Improved accuracy with directional, vacuum-assisted biopsy. Radiology 1997;202:843-847.
5. Darling ML, Smith DN, Lester SC et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: Results of surgical excision. AJR Am J Roentgenol 2000;175:1341-1346.
6. Bonnett M, Wallis T, Rossmann M et al. Histologic and radiographic analysis of ductal carcinoma in situ diagnosed using stereotactic incisional core breast biopsy. Mod Pathol 2002;15:95-101.
7. Morrow M, O'Sullivan MJ. The dilemma of DCIS. Breast 2007 Aug 20; [Epub ahead of print].
8. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231-273.
9. O'Connell P, Pekkel V, Fuqua S et al. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994;32:5-12.
10. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis. Cancer 1999;85:616-628.
11. Fisher ER, Dignam J, Tan-Chiu E et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal carcinoma. Cancer 1999;86:429-438.
12. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381-3387.
13. Lagios MD, Margolin FR, Westdahl PR et al. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63:618-624.
14. Meijnen P, Oldenburg HS, Loo CE et al. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg 2007;94:952-956.
15. Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer 1980;46(4 suppl):919-925.
16. Collins LC, Tamimi RM, Baer HJ et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: Results from the Nurses' Health Study. Cancer 2005;103:1778-1784.
17. Sanders ME, Schuyler PA, Dupont WD et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481-2484.
18. Rosner D, Bedwani RN, Vana J et al. Noninvasive breast carcinoma: Results of a national survey by the American College of Surgeons. Ann Surg 1980;192:139-147.
19. Stomper PC, Connolly JL, Meyer JE et al. Clinically occult ductal carcinoma in situ detected with mammography: Analysis of 100 cases with radiologic-pathologic correlation. Radiology 1989;172:235-241.
20. Ikeda DM, Andersson I. Ductal carcinoma in situ: Atypical mammographic appearances. Radiology 1989;172:661-666.
21. Stomper PC, Geradts J, Edge SB et al. Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass. AJR Am J Roentgenol 2003;181: 1679-1684.
22. Orel SG, Mendonca MH, Reynolds C et al. MR imaging of ductal carcinoma in situ. Radiology 1997;202:413-420.
23. Kuhl CK, Schrading S, Bieling HB et al. MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet 2007;370: 485-492.
24. Nielsen M, Thomsen JL, Primdahl S et al. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-819.
25. Graversen HP, Blichert-Toft M, Dyreborg U et al. In situ carcinomas of the female breast. Incidence, clinical findings and DBCG proposals for management. Acta Oncol 1988;27:679-682.
26. Moore MM. Treatment of ductal carcinoma in situ of the breast. Semin Surg Oncol 1991;7:267-270.
27. Silverstein MJ, Cohlan BF, Gierson ED et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer 1992;28:630-634.
28. Silverstein MJ, Lagios MD, Groshen S et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-1461.
29. Solin LJ, Kurtz J, Fourquet A et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996;14:754-763.
30. White J, Levine A, Gustafson G et al. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1995;31:791-797.
31. Solin LJ, Yeh IT, Kurtz J et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 1993;71:2532-2542.
32. Bijker N, Peterse JL, Duchateau L et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001;19:2263-2271.
33. Page DL, Dupont WD, Rogers LW et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-1200.
34. Allred DC, Bryant J, Land S et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP protocol B-24. Breast Cancer Res Treat 2002; 76(suppl 1):36.
35. Houghton J, George WD, Cuzick J et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial. Lancet 2003;362:95-102.
36. Baxter NN, Virnig BA, Durham SB et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004;96:443-448.
37. Silverstein MJ, Gierson ED, Colburn WJ et al. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 1991;172: 211-214.
38. Mabry H, Giuliano AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg 2006;192:455-457.
39. Klauber-DeMore N, Tan LK, Liberman L et al. Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000;7: 636-642.
40. Intra M, Veronesi P, Mazzarol G et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003; 138:309-313.
41. Yen TW, Hunt KK, Ross MI et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005;200:516-526.
42. Fisher B, Costantino J, Redmond C et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328:1581-1586.
43. Fisher B, Land S, Mamounas E et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001;28: 400-418.
44. Fisher B, Dignam J, Wolmark N et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-452.
45. Julien JP, Bijker N, Fentiman IS et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355:528-533.
46. Adepoju LJ, Symmans WF, Babiera GV et al. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 2006;106:42-50.
47. Macdonald HR, Silverstein MJ, Lee LA et al. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. Am J Surg 2006;192:420-422.
48. Wong JS, Kaelin CM, Troyan SL et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006;24:1031-1036.
49. Hughes L, Wang M, Page D et al. Five year results of intergroup study E5194: Local excision alone (without radiation treatment) for selected patients with ductal carcinoma in situ (DCIS). Breast Cancer Res Treat 2006; 100(suppl 1):S15.
50. Kuerer HM, Julian TB, Strom EA et al. Accelerated partial breast irradiation after conservative surgery for breast cancer. Ann Surg 2004;239:338-351.
51. Jeruss JS, Vicini FA, Beitsch PD et al. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite Clinical Trial for Ductal Carcinoma In Situ of the Breast. Ann Surg Oncol 2006;13:967-976.
52. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
53. Yen TW, Hunt KK, Mirza NQ et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 2004;100:942-949.
54. Yen TW, Kuerer HM, Ottesen RA et al. Impact of randomized clinical trial results on the use of tamoxifen (TAM) following breast surgery for ductal carcinoma in situ (DCIS) in the National Comprehensive Cancer Network (NCCN). Breast Cancer Res Treat 2006;100(suppl 1):S75.
55. Kuerer HM, Singletary SE, Buzdar AU et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 2001;182:601-608.
56. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
57. Cance WG, Carey LA, Calvo BF et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: Effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002;236:295-302; discussion 302-303.
58. Esserman L, Sepucha K, Ozanne E et al. Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol 2004;11(1 suppl):28S-36S.
59. Hwang ES, Esserman L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: Trial design and preliminary results. Ann Surg Oncol 2004; 11(suppl 1):37S-43S.
60. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
61. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
62. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5655.
63. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85-95.
64. Lewis GD, Figari I, Fendly B et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-263.
65. Bijker N, Peterse JL, Duchateau L et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001; 84:539-544.
66. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in nodenegative breast carcinomas. J Clin Oncol 1997;15:2894-2904.
67. Rakovitch E, Franssen E, Kim J et al. A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003;77:285-293.
68. Page DL, Dupont WD, Rogers LW et al. Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer 1982;49:751-758.
69. Eusebi V, Feudale E, Foschini MP et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994;11:223-235.